Search PubMed⌕ Search

Biomedical subjects

M Maruoka

Publications and source records attributed to M Maruoka.

At least 37 records · Page 2Linked to original sources
PubMed1990

[Surgical treatment of renal cell carcinoma with bone metastasis].

Eighty-six patients with renal cell carcinoma underwent radical nephrectomy in Chiba Cancer Center Hospital. Fifteen of the 86 patients developed bone metastases. Seven of the 15 patients with bone metastases had received chemotherapy and radiotherapy. Six of the 15 patients underwent surgical treatment and two received radiotherapy alone. Of the six patients treated surgically for bone metastases, two patients were treated with wide resection and the remaining four patients underwent excision of the metastatic lesions in combination with radiotherapy, chemotherapy or immunotherapy. One of the two patients who underwent wide resection of a pelvic bone lesion is alive without evidence of disease for 6 years and 4 months. Another patient who underwent wide resection of femoral bone lesion survived for 14 years and 2 months but died of recurrent cancer. Pathologic findings of renal cell carcinoma in the long-time survivors showed adenocarcinoma of alveolar type of clear cell subtype and in grade 1. Wide resection of bone metastases of renal cell carcinoma can significantly prolong the survival time and improve the quality of life of the patients.

Aged↗
PubMed1989

[Results of the treatment of carcinoma of the renal pelvis and ureter].

Twenty-one patients with renal pelvic carcinoma and eighteen patients with ureteral carcinoma were treated with surgical therapy. In 14 of the 39 patients, we performed nephroureterectomy with a bladder cuff (NUpB), nephroureterectomy with total cystectomy (NUtB) in 12, nephrectomy with partial ureteric resection (NpU) in 8 and others in 5. Following surgery, 8 had recurrences and metastasis and 21 died with carcinoma and 10 survived without evidence of disease. The 5-year survival rate of the patients with renal pelvis carcinoma is 33.5% and 52.0% in ureteral carcinoma.

Adult↗
PubMed1989

[A multimodal treatment of prostatic carcinoma and the 5-year survival rate].

One hundred and twenty-nine patients with prostatic carcinoma were treated in our hospital. They were between 49 and 88 (average, 70.3) years old and histological diagnosis was adenocarcinoma in all 129 patients; 42 had well differentiated, 55 moderately differentiated, 31 had poorly differentiated carcinomas, and one undeterminated type. Twenty two patients had stage A carcinoma, 18 stage B, 14 stage C and 75 stage D. As the therapeutic principle no castration was done, radiation therapy was delivered to cases with carcinoma more advanced than stage B in combination with estrogen or alone, and antimetabolites were given to some patients. Cryosurgical procedure to prostate was adjunctively used in patients with dysuria. Since 1986, total prostatectomy was carried out in patients with stage B disease and younger than 60 years old, and total combined resection of the urinary bladder and prostate was performed in patients with more advanced than stage C disease. Etoposide was given to patients with recurrent or metastatic lesions. Twenty-two of the 124 patients who did not receive castration surgery were categorized in stage A, 17 in stage B, 14 in stage C, and 71 in stage D. The 5-year survival rate in each stage group was 100%. 56.2%, 70.0%, and 28.8%, respectively, and the statistical difference between stage A and B, and between stage C and D was respectively significant. The relative 5-year survival rate among the total patient group, 71 patients in stage D, 40 patients in stage D treated with hormone therapy, and 15 patients in stage D treated with radiation therapy was 44.5, 28.7, 18.4 and 36.1%, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

Adenocarcinoma↗
PubMed1988

[Malignant melanoma of the penis associated with von Recklinghausen's neurofibromatosis: report of a case].

A 69-year-old male patient visited our clinic with complaints of dysuria and bleeding at the glans of penis on May 2, 1985. At the first presentation the tumor mass with necrotic and hemorrhagic character was localized around the urethral orifice and the entire glans of penis had a hard consistency. Moreover, numerous soft cutaneous nodules ranging from a small bean to a hen's egg in size spread over the total body surface. The nodules varied in property from even in height on the skin surface, half-spherical, and pedunculated. His family history was not contributory as far as neurofibromatosis was concerned. On May 15, the glans of penis was amputated and histological diagnosis was malignant melanoma with marked vascular and neural permeation. Review of the literature showed that our patient is the third case of malignant melanoma associated with neurofibromatosis in Japan.

Aged↗
PubMed1988

A case of bile duct cancer treated by laser via percutaneous transhepatic choledochoscopy.

Palliative treatment of bile duct cancer with Nd: YAG laser irradiation via percutaneous transhepatic choledochoscopy (PTCS) was performed in an 86-year-old man. The obstructed lumen of the lower common bile duct, 3 cm in length, was adequately reopened, and a further endoprosthesis insertion was not required. Symptomatic and subjective improvements were achieved with no complications, and there is no sign of recurrence after 9 months at the time of writing. This method of treatment is recommended for bile duct cancers to obtain long-term and adequate bile flow without catheter insertion.

Adenocarcinoma, Papillary↗
PubMed1983

[Tumor marker in urology].

Tumor marker for tumors in urology has been widely used to testicular and prostatic tumors. A part of testicular tumor produces alpha-fetoprotein (AFP) and HCG, thus these markers can not be used for early detection of disease. However, they are very useful in typing testicular tumor, and in monitoring a course of disease which produces them. beta-HCG seems to be more specific than HCG. In case of prostatic cancer, prostatic acid phosphatase (PAP) assayed immunochemically is sensitive and specific marker. Prostate antigen seems to be another excellent marker for this tumor, and this is well correlated with PAP. In reactivated case, tissue polypeptide antigen was elevated, suggesting use of this marker.

Acid Phosphatase↗
PubMed1982

2-amino-2-deoxy-D-erythrose in Agaricus bisporus.

2-Amino-2-deoxy-D-erythrose was isolated from the cell wall of the fruit body of Agaricus bisporus. The structure of the amino sugar was determined by mass spectrography and 1H-NMR spectrography of its acetylated derivative and by paper chromatographic comparisons with authentic 2-amino-2-deoxy-D-erythrose. This amino sugar is a component of the glycoprotein fraction from the cell wall. Its content in the glycoprotein increased markedly, especially during the ripening stage of the fruit body.

Agaricales↗
PubMed1981

Androphilic proteins in the human prostate.

Dihydrotestosterone-binding protein in cytosols from human prostates was different from the R1881- and R5020-binding proteins. The R1881- and R5020-binding proteins in the cytosol were very similar and most of the binding sites for R1881 were capable of binding R5020. However, nuclear extracts showed equal binding to dihydrotestosterone and R1881, but not to R5020, suggesting that there might not be a progestin receptor in the human prostate. Maximum binding sites to dihydrotestosterone, R1881, and R5020 in cytosols were very similar among "normal" and pathological prostates except that dihydrotestosterone binding was higher in "normal" prostates than in the pathological ones. Histochemically, R1881-binding was observed in the epithelial cells and in malignant cells, but not in the stroma.

Androgen-Binding Protein↗